Grabar Law Office Investigates Claims on Behalf of Shareholders of Pacira Biosciences Inc. (PCRX)

Philadelphia, Pennsylvania--(Newsfile Corp. - May 27, 2025) - If you have held Pacira BioSciences Inc. (NASDAQ: PCRX) shares since prior to August 2, 2023, and would like to learn more about the investigation and your rights, please visit https://grabarlaw.com/the-latest/pacira-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085.

Grabar Law Office is investigating whether certain officers and directors of Pacira breached their fiduciary duties owed to the company.

Why: A recently filed securities fraud class action complaint alleges that Pacira (NASDAQ: PCRX), via certain of its officers, disseminated materially false and misleading statements and/or concealed material adverse facts concerning the validity and scope of the Company's patents. On August 9, 2024, Pacira announced that the New Jersey District Court had invalidated its '495 patent. This announcement surprised investors and analysts alike as they reacted immediately to the revelations, and the price of Pacira's common stock declined dramatically.

What You Can Do Now: Current Pacira shareholders who have held Pacira shares since prior to August 2, 2023, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/pacira-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.

Attorney Advertising Disclaimer

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253577